The Second Dimension-Integrating Calculated Tumor Area Into Cancer Diagnosis. Read more about The Second Dimension-Integrating Calculated Tumor Area Into Cancer Diagnosis.
The Morphology of Tumor Progression in Melanoma In Situ. Read more about The Morphology of Tumor Progression in Melanoma In Situ.
Association of Disease Recurrence With Survival Outcomes in Patients With Cutaneous Squamous Cell Carcinoma of the Head and Neck Treated With Multimodality Therapy. Read more about Association of Disease Recurrence With Survival Outcomes in Patients With Cutaneous Squamous Cell Carcinoma of the Head and Neck Treated With Multimodality Therapy.
Adapting to the Effects of Climate Change in the Practice of Dermatology-A Call to Action. Read more about Adapting to the Effects of Climate Change in the Practice of Dermatology-A Call to Action.
Association of HLA Antigen Mismatch With Risk of Developing Skin Cancer After Solid-Organ Transplant. Read more about Association of HLA Antigen Mismatch With Risk of Developing Skin Cancer After Solid-Organ Transplant.
Clinical Features of Neutrophilic Dermatosis Variants Resembling Necrotizing Fasciitis. Read more about Clinical Features of Neutrophilic Dermatosis Variants Resembling Necrotizing Fasciitis.
Evaluation of a Brief Dermatologist-Delivered Intervention vs Usual Care on Sun Protection Behavior. Read more about Evaluation of a Brief Dermatologist-Delivered Intervention vs Usual Care on Sun Protection Behavior.
Targeting Tropomyosin Receptor Kinase in Cutaneous CYLD Defective Tumors With Pegcantratinib: The TRAC Randomized Clinical Trial. Read more about Targeting Tropomyosin Receptor Kinase in Cutaneous CYLD Defective Tumors With Pegcantratinib: The TRAC Randomized Clinical Trial.
Clinical, Biochemical, and Genetic Characterization of North American Patients With Erythropoietic Protoporphyria and X-linked Protoporphyria. Read more about Clinical, Biochemical, and Genetic Characterization of North American Patients With Erythropoietic Protoporphyria and X-linked Protoporphyria.